"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,A1,US 2018/0211040 A1,067-095-563-149-315,2018-07-26,2018,US 201715642093 A,2017-07-05,US 201715642093 A;;US 201715414579 A,2017-01-24,BEHAVIOR-BASED RANSOMWARE DETECTION,"An anti-malware application detects, stops, and quarantines ransomware. The anti-malware application monitors threads executing on a computing device and detects behaviors that conform to a predefined set of behaviors indicative of ransomware. Responsive to detecting these behaviors, indicators are stored to a log in a storage device. Each of the indicators in the log is associated with respective scores. A running score for each thread is generated by combining the respective scores of the indicators in the log. Responsive to determining that the running score exceeds a predefined threshold score, execution of the thread is terminated. The source ransomware file is then identified and quarantined.",MALWAREBYTES INC,PATTON MARK WILLIAM;;ITUIÑO ARES LOPEZ,MALWAREBYTES INC (2017-04-11),https://lens.org/067-095-563-149-315,Patent Application,yes,15,6,3,3,0,G06F21/566;;G06F21/566;;G06F21/568;;G06F21/568,G06F21/56,,0,0,,,,ACTIVE
2,US,B1,US 9734337 B1,106-467-374-661-309,2017-08-15,2017,US 201715414579 A,2017-01-24,US 201715414579 A,2017-01-24,Behavior-based ransomware detection,"An anti-malware application detects, stops, and quarantines ransomware. The anti-malware application monitors threads executing on a computing device and detects behaviors that conform to a predefined set of behaviors indicative of ransomware. Responsive to detecting these behaviors, indicators are stored to a log in a storage device. Each of the indicators in the log is associated with respective scores. A running score for each thread is generated by combining the respective scores of the indicators in the log. Responsive to determining that the running score exceeds a predefined threshold score, execution of the thread is terminated. The source ransomware file is then identified and quarantined.",MALWAREBYTES INC,PATTON MARK WILLIAM;;ITUIÑO ARES LOPEZ,MALWAREBYTES INC (2017-04-11),https://lens.org/106-467-374-661-309,Granted Patent,yes,26,47,3,3,0,G06F21/566;;G06F21/566;;G06F21/568;;G06F21/568,G06F21/56,,3,1,064-854-225-759-773,10.1109/icdcs.2016.46,"Kleczynski, Marcin. “Introducing the Malwarebytes Anti-Ransomware Beta,” Apr. 1, 2016, blog.malwarebytes.com/malwarebytes-news/2016/01/introducing-the-malwarebytes-anti-ransomware-beta/.;;“CryptoMonitor—Stop all known crypto-ransomware before it encrypts your data!”, Apr. 3, 2015, www.bleepingcomputer.com.;;Scaife, N. et al., “CrytoLock (and Drop It): Stopping Ransomware Attacks on User Data,” 2016 IEEE 36th International Conference on Distributed Computing Systems, IEEE, 2016, pp. 303-312.",ACTIVE
3,US,B1,US 10032025 B1,168-467-546-503-809,2018-07-24,2018,US 201715642093 A,2017-07-05,US 201715642093 A;;US 201715414579 A,2017-01-24,Behavior-based ransomware detection,"An anti-malware application detects, stops, and quarantines ransomware. The anti-malware application monitors threads executing on a computing device and detects behaviors that conform to a predefined set of behaviors indicative of ransomware. Responsive to detecting these behaviors, indicators are stored to a log in a storage device. Each of the indicators in the log is associated with respective scores. A running score for each thread is generated by combining the respective scores of the indicators in the log. Responsive to determining that the running score exceeds a predefined threshold score, execution of the thread is terminated. The source ransomware file is then identified and quarantined.",MALWAREBYTES INC,PATTON MARK WILLIAM;;ITUIÑO ARES LOPEZ,MALWAREBYTES INC (2017-04-11),https://lens.org/168-467-546-503-809,Granted Patent,yes,37,5,3,3,0,G06F21/566;;G06F21/566;;G06F21/568;;G06F21/568,G06F21/56,,4,1,064-854-225-759-773,10.1109/icdcs.2016.46,"Kleczynski, Marcin. “Introducing the Malwarebytes Anti-Ransomware Beta,” Apr. 1, 2016, blog.malwarebytes.com/malwarebytes-news/2016/01/introducing-the-malwareby-tes-anti-ransomware-beta/.;;“CryptoMonitor—Stop all known crypto-ransomware before it encrypts your data!”, Apr. 3, 2015, www.bleepingcomputer.com.;;Scaife, N. et al., “CrytoLock (and Drop It): Stopping Ransomware Attacks on User Data,” 2016 IEEE 36.sup.th International Conference on Distributed Computing Systems, IEEE, 2016, pp. 303-312.;;EasySyncSolutions, CryptoMonitor, EasySync, 2015, May be Retrieved at<URL:https://web.archive.org/web/20150406000422/http://www.easysyncsolutions.com:80/cryptomonitordetails.html>.",ACTIVE
4,US,S,US D0507747 S,133-520-901-777-880,2005-07-26,2005,US 19231503 F,2003-10-22,US 19231503 F,2003-10-22,Container,,PROCTER & GAMBLE,KERR GEORGE SCOTT;;WINKLER WILLIAM M;;MARASLIGILLER ARES,PROCTER & GAMBLE COMPANY THE (2003-12-30),https://lens.org/133-520-901-777-880,Design Right,no,0,2,1,1,0,,,0901;;D 9521;;D9/552;;D9/558,0,0,,,,EXPIRED
5,US,S,US D0508406 S,173-139-227-561-399,2005-08-16,2005,US 19232203 F,2003-10-22,US 19232203 F,2003-10-22,Container,,PROCTER & GAMBLE,KERR GEORGE SCOTT;;WINKLER WILLIAM M;;MARASLIGILLER ARES,PROCTER & GAMBLE COMPANY THE (2003-12-30),https://lens.org/173-139-227-561-399,Design Right,no,0,1,1,1,0,,,0901;;D 9521;;D9/552;;D9/571,0,0,,,,EXPIRED
6,DE,D1,DE 60025841 D1,029-556-169-877-665,2006-04-13,2006,DE 60025841 T,2000-11-07,US 46143899 A;;US 0030612 W,1999-12-14,CHEMISCHE DISPERGIERSUBSTANZ FÜR ÖLUNFÄLLE,,EXXONMOBIL RES & ENG CO,LESSARD RAYMOND;;BECKER WILLIAM;;CANEVARI PAUL;;GEORGE-ARES ANITA;;FIOCCO JOHN,,https://lens.org/029-556-169-877-665,Granted Patent,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C02F1/68;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
7,AU,A,AU 1986/057218 A,009-780-339-123-921,1987-11-12,1987,AU 1986/057218 A,1986-05-07,US 76142685 A,1985-08-01,FLOW-THROUGH SURGE RECEIVER,,HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/009-780-339-123-921,Patent Application,no,0,0,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,,0,0,,,,EXPIRED
8,FR,A1,FR 2585813 A1,114-394-136-842-601,1987-02-06,1987,FR 8610576 A,1986-07-21,US 76142685 A,1985-08-01,RESERVOIR-TAMPON A ECOULEMENT DIRECT,"<P>CE RESERVOIR-TAMPON 16, DESTINE A UN SYSTEME FRIGORIFIQUE COMPORTANT DES COMPRESSEURS 1, 2, UN CONDENSEUR 10 ET DES EVAPORATEURS 26 A 29, FORME UNE CHAMBRE 17 DE LIQUIDE FRIGORIGENE. UN TUYAU 50 D'ECOULEMENT DIRECT, TRAVERSANT CETTE CHAMBRE, COMPORTE UNE ENTREE 51 POUR RECEVOIR LE LIQUIDE FRIGORIGENE DU CONDENSEUR ET UNE SORTIE 52 POUR ENVOYER CE LIQUIDE FRIGORIGENE VERS LES EVAPORATEURS SANS LE FAIRE PASSER DANS LA CHAMBRE DU RESERVOIR. UN MOYEN 54 ETABLIT UNE COMMUNICATION DE FLUIDE ENTRE LE TUYAU ET LE RESERVOIR AU-DESSOUS DU NIVEAU NORMAL DE LIQUIDE FRIGORIGENE CONTENU DANS LE RESERVOIR.</P><P>APPLICATIONS : NOTAMMENT AUX SYSTEMES FRIGORIFIQUES DE SUPERMARCHES ET D'ENTREPOTS, CASIERS ET MANUFACTURES.</P>",HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/114-394-136-842-601,Patent Application,no,0,1,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,,0,0,,,,DISCONTINUED
9,US,A,US 5663189 A,083-613-727-239-753,1997-09-02,1997,US 47870895 A,1995-06-07,US 47870895 A;;US 8648293 A,1993-07-01,2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists,"The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3; (b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S; (c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and (d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating one or more of respiratory disorders, ocular disorders, and gastrointestinal disorders.",PROCTER & GAMBLE,MAURER PETER JULIAN;;ARES JEFFREY JOSEPH;;SEIBEL WILLIAM LEE;;WALKER DANIEL P,PROCTER & GAMBLE COMPANY THE (1995-08-17),https://lens.org/083-613-727-239-753,Granted Patent,yes,7,10,1,3,0,A61K31/4178;;A61K31/4178;;C07D405/12;;C07D405/12,A61K31/4178;;C07D405/12,514/397;;548/311.4;;548/311.7,4,3,036-707-528-796-71X;;040-445-510-060-031;;013-502-014-709-435,6311568;;10.1016/0014-2999(83)90373-4;;10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046,"Chapleo, C.B., J. C. Doxey, L. W. Frank, P.L. Myers, A.G. Roach, C.F.C. Smith & N.K. Virdee, Comparison of the Adrenoceptor Profiles of Clonidine and Two Oxygenated Arylamino Imidazolines , European Journal of Pharmacology, vol. 91 (1983), pp. 123 128.;;Chapleo, C.B., J.C. Doxey, P.L. Myers, M. Myers, C.F.C. Smith & M.R. Stillings, Effect of 1,4 Dioxanyl Substitution on the Adrenergic Activity of Some Standard Adrenoreceptor Agents , European Journal of Medical Chemistry, vol. 24 (1989), pp. 619 622.;;Chapleo, C.B., R.C.M. Butler, D.C. England, P.L. Myers, A.G. Roach, C.F.C. Smith, M.R. Stillings & I.F. Tulloch, Heteroaromatic Analogues of the 2 Adrenoreceptor Partial Agonist Clonidine , Journal of Medical Chemistry, vol. 32 (1989), pp. 1627 1630.;;Clare, K.A., M.C. Scrutton & N.T. Thompson, Effects of 2 Adrenoreceptor Agonists and of Related Compounds on Agregation of, and on Adenylate Cyclase Activity in, Human Platelets , British Journal of Pharmacology, vol. 82 (1984), pp. 467 476.",EXPIRED
10,GB,A,GB 2178514 A,195-886-984-962-453,1987-02-11,1987,GB 8612450 A,1986-05-22,US 76142685 A,1985-08-01,A FLOW-THROUGH SURGE RECEIVER FOR A REFRIGERATION SYSTEM,,HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/195-886-984-962-453,Patent Application,no,2,0,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,F4H HGXS          HGXS;;F4H HG15          HG15;;F4H HG2A          HG2;;F4H HG2J          HG2;;F4H HG2L          HG2;;F4H HG2M          HG2;;F4H HG2N          HG2;;F4H HG2S          HG2,0,0,,,,EXPIRED
11,US,A,US 4621505 A,074-441-980-659-589,1986-11-11,1986,US 76142685 A,1985-08-01,US 76142685 A,1985-08-01,Flow-through surge receiver,"A flow-through surge receiver for a refrigeration system having compressor, condenser and evaporator means, in which a surge-type receiver forms a reservoir for liquid refrigerant and has a flow-through conduit receiving refrigerant from the condenser means and an outlet for passing such refrigerant directly to the evaporator means in by-pass relation with the receiver reservoir, and a passageway for establishing fluid communication between said conduit and reservoir below the normal liquid refrigerant level in the reservoir.",HUSSMANN CORP,ARES ROLAND A;;CROMER JAMES M;;SCHAEFFER WAYNE G;;WEHMEIER WILLIAM C,HUSSMANN CORPORATION A CORP OF DE (1985-07-16),https://lens.org/074-441-980-659-589,Granted Patent,yes,16,89,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F02B1/04;;F25B1/00;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,62/509;;62/196.4;;62/510,0,0,,,,EXPIRED
12,AU,B2,AU 578580 B2,106-410-911-589-49X,1988-10-27,1988,AU 1986/057218 A,1986-05-07,US 76142685 A,1985-08-01,FLOW-THROUGH SURGE RECEIVER,,HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/106-410-911-589-49X,Granted Patent,no,1,0,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,,0,0,,,,EXPIRED
13,CA,A,CA 1236988 A,079-865-477-605-197,1988-05-24,1988,CA 508037 A,1986-04-30,US 76142685 A,1985-08-01,FLOW-THROUGH SURGE RECEIVER,"A flow-through surge receiver for a refrigeration system having compressor, condenser and evaporator means, in which the receiver forms a reservoir for liquid refrigerant and has flow-through conduit means with an inlet to receive refrigerant from the condenser means and an outlet for passing such refrigerant to the evaporator means in by-pass relation with the receiver reservoir, and means establishing fluid communication between said conduit and reservoir below the normal liquid refrigerant level in the reservoir.",HUSSMANN CORP,ARES ROLAND A;;CROMER JAMES M;;SCHAEFFER WAYNE G;;WEHMEIER WILLIAM C,,https://lens.org/079-865-477-605-197,Granted Patent,no,0,0,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,62-47,0,0,,,,EXPIRED
14,DE,A1,DE 3625292 A1,139-746-776-909-310,1987-02-05,1987,DE 3625292 A,1986-07-25,US 76142685 A,1985-08-01,DRUCKGEREGELTER DURCHLAUFSAMMLER,,HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/139-746-776-909-310,Patent Application,no,0,3,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,,0,0,,,,DISCONTINUED
15,GB,B,GB 2178514 B,078-774-554-408-868,1989-12-20,1989,GB 8612450 A,1986-05-22,US 76142685 A,1985-08-01,FLOW-THROUGH SURGE RECEIVER,,HUSSMANN CORP,ARES ROLAND ANDREW;;CROMER JAMES MERRILL;;SCHAEFFER WAYNE GERALD;;WEHMEIER WILLIAM CARL,,https://lens.org/078-774-554-408-868,Granted Patent,no,2,0,10,10,0,F02B1/04;;F25B5/02;;F25B41/00;;F25B47/022;;F25B2400/075;;F25B2400/16;;F25B2400/22;;F25B41/22;;F25B5/02;;F25B2400/16;;F02B1/04;;F25B41/00;;F25B2400/22;;F25B2400/075;;F25B47/022;;F25B41/22,F25B1/00;;F02B1/04;;F25B5/02;;F25B41/00;;F25B41/04;;F25B43/00;;F25B47/02,F4H HG15          HG15;;F4H HG2A          HG2;;F4H HG2J          HG2;;F4H HG2L          HG2;;F4H HG2M          HG2;;F4H HG2N          HG2;;F4H HG2S          HG2,0,0,,,,EXPIRED
16,US,A1,US 2023/0052045 A1,013-963-520-606-238,2023-02-16,2023,US 202217877864 A,2022-07-29,US 202217877864 A;;US 202163227343 P,2021-07-30,METHODS OF MAKING POROUS DEVICES FROM MONODISPERSE POPULATIONS OF POLYARYLKETONE OR POLYARYLTHIOETHERKETONE PARTICLES,"The invention provides methods for making porous devices from substantially monodisperse populations of substantially spherical particles of polyarylketone polymers or of thio-analogues of such polymers, of selected sizes. The porous devices allow greater control of porosity than previously available porous devices. In some embodiments, the porous devices are frits, filters, membranes or monoliths.",AGILENT TECHNOLOGIES INC,DAVIES JOHN WILLIAM;;COBB THOMAS JACOB;;GEOVANOS ARES;;WILBANKS THOR MILLER;;BAI QING,AGILENT TECHNOLOGIES INC (2021-09-15),https://lens.org/013-963-520-606-238,Patent Application,yes,0,0,2,2,0,C08J9/24;;C08J2371/10;;C08J2381/02;;B29C43/006;;B29C43/02;;B29K2071/00;;G01N2030/524;;G01N30/52;;G01N2030/8831;;C08G65/48;;C08G2650/40;;C08J9/24;;C08J3/14;;C08G2650/40;;C08G65/48;;C08J2371/00;;C08G65/4056,C08J9/24;;C08G65/40;;C08G65/48;;C08J3/14,,0,0,,,,PENDING
17,CA,A1,CA 2396786 A1,181-181-963-117-850,2001-06-21,2001,CA 2396786 A,2000-11-07,US 46143899 A;;US 0030612 W,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,"A formulation of chemical surfactants, solvents and inorganic salts is effective for dispersing heavy oils in both salt and fresh water. The formulation comprises a mixture of a sorbitan ester of an aliphatic monocarboxylic acid, a polyoxyethylene adduct of a sorbitan monoester of an aliphatic monocarboxylic acid, an alkali metal salt of a dialkyl sulfosuccinate, a polyoxyethylene adduct of a sorbitan triester of a monocarboxylic acid, a solvent comprising a hydrocarbon and/or a glycol ethe r and an inorganic salt containing a soluble divalent cation such as calcium o r magnesium.",EXXON RESEARCH ENGINEERING CO,GEORGE-ARES ANITA;;CANEVARI GERARD PAUL;;FIOCCO ROBERT JOHN;;BECKER KENNETH WILLIAM;;LESSARD RICHARD RAYMOND,,https://lens.org/181-181-963-117-850,Patent Application,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
18,EP,A1,EP 1251947 A1,171-669-322-414-165,2002-10-30,2002,EP 00975599 A,2000-11-07,US 0030612 W;;US 46143899 A,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,,EXXONMOBIL RES & ENG CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/171-669-322-414-165,Patent Application,yes,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
19,NO,B1,NO 327051 B1,050-261-021-986-657,2009-04-14,2009,NO 20022814 A,2002-06-13,US 46143899 A;;US 0030612 W,1999-12-14,Kjemisk dispergeringsmiddel for oljesol,,EXXONMOBIL RES & ENG CO,BECKER KENNETH WILLIAM;;FIOCCO ROBERT JOHN;;LESSARD RICHARD RAYMOND;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA,,https://lens.org/050-261-021-986-657,Granted Patent,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
20,US,B1,US 6194473 B1,066-057-171-103-920,2001-02-27,2001,US 46143899 A,1999-12-14,US 46143899 A,1999-12-14,Chemical dispersant for oil spills (LAW898),"A formulation of chemical surfactants, solvents and inorganic salts is effective for dispersing heavy oils in both salt and fresh water. The formulation comprises a mixture of a sorbitan ester of an aliphatic monocarboxylic acid, a polyoxyethylene adduct of a sorbitan monoester of an aliphatic monocarboxylic acid, an alkali metal salt of a dialkyl sulfosuccinate, a polyoxyethylene adduct of a sorbitan triester of a monocarboxylic acid, a solvent comprising a hydrocarbon and/or a glycol ether and an inorganic salt containing a soluble divalent cation such as calcium or magnesium.",EXXON RESEARCH ENGINEERING CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,EXXONMOBIL RESEARCH & ENGINEERING CO (1999-11-23),https://lens.org/066-057-171-103-920,Granted Patent,yes,8,16,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42;;C09K23/10,516/63;;210/925;;510/365,0,0,,,,EXPIRED
21,NO,L,NO 20022814 L,002-453-046-802-434,2002-07-01,2002,NO 20022814 A,2002-06-13,US 46143899 A;;US 0030612 W,1999-12-14,Kjemisk dispergeringsmiddel for oljesöl,,EXXONMOBIL RES & ENG CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/002-453-046-802-434,Abstract,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K3/32;;C09K23/00;;C09K23/34;;C09K23/10;;C09K23/42,,0,0,,,,EXPIRED
22,CA,C,CA 2396786 C,179-939-588-815-052,2009-06-02,2009,CA 2396786 A,2000-11-07,US 46143899 A;;US 0030612 W,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,"A formulation of chemical surfactants, solvents and inorganic salts is effective for dispersing heavy oils in both salt and fresh water. The formulation comprises a mixture of a sorbitan ester of an aliphatic monocarboxylic acid, a polyoxyethylene adduct of a sorbitan monoester of an aliphatic monocarboxylic acid, an alkal i metal salt of a dialkyl sulfosuccinate, a polyoxyethylene adduct of a sorbitan triester of a monocarboxylic acid, a solvent comprising a hydrocarbon and/or a glycol ether and an inorganic salt containing a soluble divalent cation such as calcium or magnesium.</SDO AB>",EXXON RESEARCH ENGINEERING CO,CANEVARI GERARD PAUL;;BECKER KENNETH WILLIAM;;FIOCCO ROBERT JOHN;;GEORGE-ARES ANITA;;LESSARD RICHARD RAYMOND,,https://lens.org/179-939-588-815-052,Granted Patent,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
23,NO,D0,NO 20022814 D0,193-267-694-984-384,2002-06-13,2002,NO 20022814 A,2002-06-13,US 46143899 A;;US 0030612 W,1999-12-14,Kjemisk dispergeringsmiddel for oljesöl,,EXXONMOBIL RES & ENG CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/193-267-694-984-384,Patent Application,no,0,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K3/32;;C09K23/00;;C09K23/34;;C09K23/10;;C09K23/42,,0,0,,,,EXPIRED
24,EP,A4,EP 1251947 A4,081-906-989-237-199,2004-11-24,2004,EP 00975599 A,2000-11-07,US 0030612 W;;US 46143899 A,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,,EXXONMOBIL RES & ENG CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/081-906-989-237-199,Search Report,no,1,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
25,EP,B1,EP 1251947 B1,166-873-945-698-974,2006-02-01,2006,EP 00975599 A,2000-11-07,US 0030612 W;;US 46143899 A,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,,EXXONMOBIL RES & ENG CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/166-873-945-698-974,Granted Patent,yes,9,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K23/10;;C02F1/68;;C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42,,0,0,,,,EXPIRED
26,WO,A1,WO 2001/043860 A1,096-679-109-599-43X,2001-06-21,2001,US 0030612 W,2000-11-07,US 46143899 A,1999-12-14,CHEMICAL DISPERSANT FOR OIL SPILLS,"A formulation of chemical surfactants, solvents and inorganic salts is effective for dispersing heavy oils in both salt and fresh water. The formulation comprises a mixture of a sorbitan ester of an aliphatic monocarboxylic acid, a polyoxyethylene adduct of a sorbitan monoester of an aliphatic monocarboxylic acid, an alkali metal salt of a dialkyl sulfosuccinate, a polyoxyethylene adduct of a sorbitan triester of a monocarboxylic acid, a solvent comprising a hydrocarbon and/or a glycol ether and an inorganic salt containing a soluble divalent cation such as calcium or magnesium.",EXXON RESEARCH ENGINEERING CO,LESSARD RICHARD RAYMOND;;BECKER KENNETH WILLIAM;;CANEVARI GERARD PAUL;;GEORGE-ARES ANITA;;FIOCCO ROBERT JOHN,,https://lens.org/096-679-109-599-43X,Patent Application,yes,8,0,11,11,0,C09K3/32;;Y10S210/925;;C09K23/017;;C09K3/32;;Y10S210/925;;C09K23/017,C09K3/32;;C09K23/00;;C09K23/34;;C09K23/42;;C09K23/10,,0,0,,,,PATENTED
27,CA,A1,CA 2272644 A1,056-783-008-203-247,1998-06-04,1998,CA 2272644 A,1997-11-21,US 3174096 P;;US 9720551 W,1996-11-25,2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having structure (I) wherein: a) R1 is hydrogen; or alkyl; b) R2 is hydrogen; alkyl or nil; c) R3 is selected from hydrogen; unsubstituted C1-C3 alkanyl; amino, hydroxy, mercapto; C1-C3 alkylthio or alkoxy; C1-C3 alkylamino or C1-C3 dialkylamino; cyano; and halo; d) R4, R5 and R7 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstitued C1C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; e) when R2 is nil, bond (a) is a double bond; f) the compound is not 7-bromo-6-(2-imidazolinylamino)indazole; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters, and pharmaceutical compositions containing such novel compounds, and the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/056-783-008-203-247,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
28,ZA,B,ZA 9710576 B,186-967-570-662-221,1998-09-16,1998,ZA 9710576 A,1997-11-25,US 3174096 P;;US 9720551 W,1996-11-25,2-imidazolinylaminoindazole compounds useful as alpha-2-adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/186-967-570-662-221,Granted Patent,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,EXPIRED
29,PE,A1,PE 16199 A1,017-566-401-665-717,1999-03-12,1999,PE 00106497 A,1997-11-25,US 3175696 P,1996-11-25,COMPUESTOS DE 2-IMIDAZOLINILAMINOBENZOTIAZOL UTILES COMO AGONISTAS DE ALFA-2 ADRENORECEPTORES,"SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1, R2 Y R3 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, OH, TIO, NITRO, CN, AMINO, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; R4 ES H, ALQUILO C1-C3, AMINO, OH, MERCAPTO, ALQUILTIO, ALCOXI C1-C3, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; R5 ES H, ALQUILO O NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; EN DONDE EL IMIDAZOLINILAMINO ESTA UNIDO EN LA POSICION 5 o 6 DEL ANILLO DE BENZOTIAZOL; UN COMPUESTO (I) PREFERIDO ES: 4-ETIL-5-(2-IMIDAZOLINILAMINO)BENZOTIAZOL. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE: UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS ALFA 2 ADRENORECEPTOR, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIAS Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS",PROCTER & GAMBLE,SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH;;SHELDON RUSSELL JAMES;;HENRY RAYMOND TODD;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA,,https://lens.org/017-566-401-665-717,Patent Application,no,0,0,6,42,0,C07D417/12,C07D417/12;;A61K31/425,,0,0,,,,DISCONTINUED
30,NO,D0,NO 992498 D0,028-701-408-845-399,1999-05-25,1999,NO 992498 A,1999-05-25,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinylheterocykelforbindelser anvendelige som <alfa>-2 adrenoceptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/028-701-408-845-399,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
31,ID,A,ID 22676 A,026-564-971-063-758,1999-12-09,1999,ID 990412 A,1997-11-21,US 3174096 P,1996-11-25,SENYAWA-SENYAWA 2-IMIDALINILAMINOINDAZOL YANG BERGUNA SEBAGAI AGONIS ADRENOSEPTOR ALFA-2,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/026-564-971-063-758,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
32,ZA,B,ZA 9710574 B,025-318-677-506-167,1998-06-10,1998,ZA 9710574 A,1997-11-25,US 3175696 P,1996-11-25,2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists.,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/025-318-677-506-167,Granted Patent,no,0,0,6,42,0,C07D417/12,C07D417/12,,0,0,,,,EXPIRED
33,EP,A1,EP 0944620 A1,116-497-747-639-498,1999-09-29,1999,EP 97948238 A,1997-11-21,US 9720551 W;;US 3174096 P,1996-11-25,2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/116-497-747-639-498,Patent Application,yes,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
34,AU,A,AU 1998/054338 A,176-585-121-358-797,1998-06-22,1998,AU 1998/054338 A,1997-11-21,US 3175696 P;;US 9720549 W,1996-11-25,2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/176-585-121-358-797,Patent Application,no,0,0,6,42,0,C07D417/12,C07D417/12,,0,0,,,,PENDING
35,ES,T3,ES 2236833 T3,036-093-845-893-405,2005-07-16,2005,ES 97948290 T,1997-11-21,US 3202396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILO UTILES COMO AGONISTAS DE RECEPTORES ADRENERGICOS ALFA 2.,"LA INVENCION SE REFIERE A COMPUESTOS QUE TIENEN LA ESTRUCTURA (I), SEGUN SE DESCRIBE EN LAS REIVINDICACIONES; ASI COMO A SUS ENANTIOMEROS, ISOMEROS OPTICOS, ESTEREOISOMEROS, DIAESTEREOMEROS, TAUTOMEROS, SALES DE ADICION, AMIDAS BIOHIDROLIZABLES Y ESTERES, ASI COMO A COMPOSICIONES FARMACEUTICAS QUE INCLUYEN DICHOS NUEVOS COMPUESTOS. LA INVENCION SE REFIERE IGUALMENTE AL USO DE TALES COMPUESTOS PARA PREVENIR O TRATAR LOS TRASTORNOS MODULADOS POR LOS ADRENOCEPTORES ALFA - 2.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/036-093-845-893-405,Granted Patent,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
36,NO,L,NO 992498 L,084-361-739-420-056,1999-07-26,1999,NO 992498 A,1999-05-25,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinylheterocykelforbindelser anvendelige som <alfa>-2 adrenoceptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/084-361-739-420-056,Abstract,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
37,HU,A2,HU P9904660 A2,189-302-787-887-176,2000-06-28,2000,HU P9904660 A,1997-11-21,US 3174096 P;;US 9720551 W,1996-11-25,2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"A találmány (I) általánős képletű vegyületekre -, ahől R1 hidrőgénatőm vagy alkilcsőpőrt, R2 hidrőgénatőm, alkilcsőpőrt vagy nincs jelen; R3 hidrőgénatőm, szűbsztitűálatlan alkilcsőpőrt, aminő-, hidrőxi-,merkaptőcsőpőrt, alkil-tiő- vagy alkőxicsőpőrt, alkil-aminő- vagydialkil-aminő-csőpőrt, és halőgénatőm, R4, R5 és R7 hidrőgénatőm, szűbsztitűálatlan alkil-, alkenil- vagyalkinilcsőpőrt, ciklőalkil-, ciklőalkenilcsőpőrt, szűbsztitűálatlanalkil-tiő- vagy alkőxicsőpőrt, hidrőxi-, merkaptő-, nitrő-, cianő-,aminő-, alkil-aminő- vagy dialkil-aminő-csőpőrt, vagy halőgénatőm, ha R2 nincs jelen, (a) kötés jelentése kettős kötés, és a vegyület 7-bróm-6-[(2-imidazőlidinilidén)-aminő]-indazőltól eltérő -, ésenantiőmereikre, őptikai izőmereikre, sztereőizőmereikre,diasztereőmereikre, taűtőmereikre, addíciós sóikra, biőhidrőlizálhatóamidjaikra és észtereikre, ezeket tartalmazó gyógyszerkészítményekre,valamint alkalmazásűkra vőnatkőzik. (I) ŕ",The Procter & Gamble Co.,ARES JEFFREY JOSEPH;;BOGDAN SOPHIE EVA;;CUPPS THOMAS LEE;;HENRY RAYMOND TODD;;SEIBEL WILLIAM LEE;;SHELDON RUSSEL JAMES,,https://lens.org/189-302-787-887-176,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
38,TR,T2,TR 199901468 T2,049-005-321-420-796,1999-10-21,1999,TR 9901468 T,1997-11-21,US 3202396 P,1996-11-25,Alfa-2 adrenoseptör agonistleri olarak yararli guanidinil heterosikl bilesikleri.,"Bu bulus Istemlerde açiklanan (I) yapisini haiz bilesiklere; bunlarin enantiomerleri, optik izomerleri, stereoizomerleri, diastereomerleri, totomerleri, ilave tuzlari, biyohidrolize edilebilir amitleri ve esterlerine ve bu yeni bilesikleri içeren farmasötik bilesimlere iliskindir. Bulus ayrica bu bilesiklerin alfa-2 adrenoseptörleri tarafindan degistirilmis bozukluklari önlemek veya tedavi etmek için kullanimina iliskindir.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/049-005-321-420-796,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
39,ZA,B,ZA 9710578 B,044-011-806-885-275,1998-06-25,1998,ZA 9710578 A,1997-11-25,US 3202396 P,1996-11-25,Guanidinyl heterocycle compounds useful as Alpha-2 adrenoceptor agonists.,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SIEBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/044-011-806-885-275,Granted Patent,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
40,CZ,A3,CZ 183999 A3,158-133-074-328-025,1999-11-17,1999,CZ 183999 A,1997-11-21,US 3174096 P,1996-11-25,"COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND PREVENTION OR TREATMENT METHOD",,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/158-133-074-328-025,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
41,US,B1,US 6172095 B1,021-980-625-004-895,2001-01-09,2001,US 30879099 A,1999-08-09,US 30879099 A;;US 3175696 P;;US 9720550 W;;US 3183396 P,1996-11-25,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,"This invention involves compounds having the structure (I) as described in the claims, and enantiomers,optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such noved compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. ##STR1##",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,THE PROCTER & GAMBLE COMPANY (1999-08-02),https://lens.org/021-980-625-004-895,Granted Patent,yes,6,9,1,42,0,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12;;C07D235/06;;C07D215/06;;C07D277/62;;A61K31/47;;C07D215/16;;C07D215/40;;C07D417/12,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12,514/394;;548/309.7,12,6,040-445-510-060-031;;013-502-014-709-435;;176-451-500-252-542;;095-061-055-274-806;;040-034-235-622-020;;010-417-946-924-13X,10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046;;6117656;;6142954;;10.1021/jm00370a011;;10.1016/0014-2999(86)90336-5;;2876906;;2876905;;10.1016/0014-2999(86)90335-3;;10.1146/annurev.pa.33.040193.001331;;10.1146/annurev.pharmtox.33.1.243;;8098595,"Chemical Abstracts 121:230777, 1994.;;Chemical Abstracts 123:275568, 1995.;;C.B. Chapleo, et al, ""Heteroaromatic Analogues of the alpha2-Adrenoceptor Partial Agonist Clonidine"", J. Med. Chem., vol. 32, pp. 1627-1630, (1989).;;Timmermans, P.B.M.W.M, et al, ""12.1 alpha-Adrenergic Receptors"", Neurotransmitter and Autocoid Receptors, pp. 133-185.;;Clare, K.A., et al., Effects of alpha2-Adrenoceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclase Activity in, Human Platelets, Br. J. Pharmac, vol. 82, pp. 467-476, (1984).;;Chapleo, C.B., ""Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of Some Standard alpha-Adrenoreceptor Agents"", Eur. J. Med. Chem., vol. 24, pp. 619-622, (1989).;;Van Meel, J.C.A., ""Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat1"", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, No. 3, pp. 760-767, (1981).;;Timmerman, P.B.M.W.M., et al., ""Quantitative Relationships Between alpha-Adrenergic Activity and Binding Affinity of alpha-Adrenoceptor Agonists and Antagonists"", J. Med. Chem., vol. 27, pp. 495-503, (1984).;;Megens, A.A.H.P., et al., ""Further Validation of in vivo and in vitro Pharmacological Procedures for Assessing the alpha2/alpha1-selectivity of Test Compounds: (2) alpha-adrenoceptor Agonists"", European Journal of Pharmacology, vol. 129, pp. 57-64, (1986).;;Timmermans, P.B.M.W.M., et al., ""alpha-Adrenoceptor Agonists and Antagonists"", Drugs of the Future, vol. 9, No. 1, pp. 41-55, (1984).;;Ruffolo, R.R., et al., ""Pharmacological & Therapeutic Applications of Alpha-2 Adrenoceptor Subtypes"", Annual Review of Pharmacology & Toxicology, vol. 32, pp. 243-279, (1993).;;Chemical Abstracts 111:187132, 1989.*",EXPIRED
42,AU,A,AU 1998/054339 A,137-379-321-123-704,1998-06-22,1998,AU 1998/054339 A,1997-11-21,US 3174096 P;;US 9720551 W,1996-11-25,2-imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/137-379-321-123-704,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
43,ES,T3,ES 2192703 T3,000-631-800-869-355,2003-10-16,2003,ES 97949399 T,1997-11-21,US 3183396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILAMINO UTILES COMO AGONISTAS ALFA-2 ADRENOCEPTORES.,"LA INVENCION SE REFIERE A COMPUESTOS QUE TIENEN LA ESTRUCTURA (I), SEGUN LAS REIVINDICACIONES; Y A LOS ENANTIOMEROS, ISOMEROS OPTICOS, ESTEREOISOMEROS, DIAESTEREOMEROS, TAUTOMEROS, SALES DE ADICION, AMIDAS BIOHIDROLIZABLES Y ESTERES DE LOS MISMOS, ASI COMO A COMPOSICIONES FARMACEUTICAS QUE INCLUYEN DICHOS COMPUESTOS NUEVOS. LA INVENCION SE REFIERE IGUALMENTE AL USO DE TALES COMPUESTOS PARA PREVENIR O TRATAR LOS TRASTORNOS MODULADOS POR LOS ADRENOCEPTORES ALFA - 2.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/000-631-800-869-355,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
44,NO,L,NO 992502 L,030-294-142-578-348,1999-07-26,1999,NO 992502 A,1999-05-25,US 3174096 P;;US 9720551 W,1996-11-25,2-Imidazolinylaminoindazolforbindelser nyttige som <alfa>-2 adrenerge reseptoragonister,"Denne oppfinnelse vedrører forbindelser som har struktur (I) hvor: a) RT er hydrogen; eller alkyl; b) R2 er hydrogen; alkyl eller null; c) R3 er valgt fra hydrogen; usub- stituert C^ alkanyl; amino, hydroksy, merkapto; C^-C, alkyltio eller alkoksy; Ci-C3 alkylamino eller C^-C3 dialkyl- amino; cyano; og halo; d) R,, Rs og R, er hver uavhengig valgt fra hydrogen; usubstituert C^-C^ alkanyl, alkenyl eller alkynyl; cykloalkanyl, cykloalkenyl; usubstituert C^- C3 alkyltio eller alkoksy; hydroksy; tio; nitro; cyano; amino; C^-Cj alkylamino eller C^-C., dialkylamino og halo; e) når R2 er null, er binding (a) en dobbeIbinding; f) for- bindelsen er ikke 7-brom-6-(2-imidazolinylamino)indazol; og enantiomerer, optiske isomerer, stereoisomerer, diastereo- merer, tautomerer, addisjonssalter, biohydrolyserbare amider og estere, og farmasøytiske sammensetninger inne- holdende slike nye forbindelser, og anvendelsen av slike forbindelser for å forhindre eller behandle forstyrrelser modulert av alfa-2-adrenerge reseptorer.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/030-294-142-578-348,Abstract,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
45,WO,A1,WO 1998/023591 A1,025-375-764-348-524,1998-06-04,1998,US 9720550 W,1997-11-21,US 3183396 P,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having the structure (I) as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/025-375-764-348-524,Patent Application,yes,2,5,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PATENTED
46,BR,A,BR 9714362 A,073-111-160-634-062,2000-03-21,2000,BR 9714362 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,agonistas de alfa-2 adrenoceptores,"ENOCEPTORES""<D>. Esta invenção envolve compostos tões, e enantiómeros, isómeros óticos, estereoisómeros, diastereómeros, tautómeros, sais de adição, amidas e ésteres bioidrolizáveis dos mesmos, bem como composições farmacêuticas compreendendo tais noo de tais compostos para evitar ou tratar sistúrbios modulados por alfa-2 adreno-ceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/073-111-160-634-062,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,DISCONTINUED
47,ZA,B,ZA 9710575 B,143-784-203-485-698,1998-06-10,1998,ZA 9710575 A,1997-11-25,US 3183396 P,1996-11-25,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists.,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/143-784-203-485-698,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;C07D215/38;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
48,NO,D0,NO 992503 D0,174-358-616-716-16X,1999-05-25,1999,NO 992503 A,1999-05-25,US 3183396 P;;US 9720550 W,1996-11-25,Guanidinylamino heterocykelforbindelser nyttige som <alfa>-2 adrenerge reseptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/174-358-616-716-16X,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;C07D215/38;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
49,AT,T1,AT E286885 T1,185-868-681-047-328,2005-01-15,2005,AT 97948290 T,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,GUANIDYL-HETEROCYCLISCHE VERBINDUNGEN ALS ALPHA-2 ADRENOCEPTOR AGONISTEN,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/185-868-681-047-328,Granted Patent,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,DISCONTINUED
50,EP,A1,EP 0944604 A1,185-315-405-148-173,1999-09-29,1999,EP 97948290 A,1997-11-21,US 9720802 W;;US 3202396 P,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/185-315-405-148-173,Patent Application,yes,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
51,US,B1,US 6225331 B1,074-954-323-749-49X,2001-05-01,2001,US 30878899 A,1999-08-09,US 30878899 A;;US 3202396 P;;US 9720802 W,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,"This invention involves compounds having the following structure: ##STR1## as described in the claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,PROCTER & GAMBLE COMPANY THE (1998-01-16);;THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (2005-05-06),https://lens.org/074-954-323-749-49X,Granted Patent,yes,9,33,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,514/367;;514/375;;514/394;;514/406;;514/414;;514/415;;548/152;;548/217;;548/309.7;;548/362.5;;548/157,12,6,040-445-510-060-031;;013-502-014-709-435;;176-451-500-252-542;;095-061-055-274-806;;040-034-235-622-020;;010-417-946-924-13X,10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046;;6117656;;6142954;;10.1021/jm00370a011;;10.1016/0014-2999(86)90336-5;;2876906;;2876905;;10.1016/0014-2999(86)90335-3;;10.1146/annurev.pa.33.040193.001331;;10.1146/annurev.pharmtox.33.1.243;;8098595,"Chemical Abstracts 102:168273, 1984.*;;Chemical Abstracts, 132:260666, Dykens, 2000.*;;Chemical Abstracts 132:233047, Hasegawa, 2000.*;;C.B. Chapleo, et al, ""Heteroaromatic Analogues of the alpha2-Adrenoceptor Partial Agonist Clonidine"", J. Med. Chem., vol. 32, pp. 1627-1630, (1989).;;Timmermans, P.B.M.W.M, et al, ""12.1 alpha-Adrenergic Receptors"", Neurotransmitter and Autocoid Receptors, pp. 133-185, 1990.;;Clare, K.A., et al., Effects of alpha2-Adrenoceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclase Activity in, Human Platelets, Br. J. Pharmac, vol. 82, pp. 467-476, (1984).;;Chapleo, C.B., ""Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of Some Standard alpha-Adrenoreceptor Agents"", Eur. J. Med. Chem., vol. 24, pp. 619-622(1989).;;Van Meel, J.C.A., ""Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat1"", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, No. 3, pp. 760-767, (1981).;;Timmerman, P.B.M.W.M., et al., ""Quantitative Relationships Between alpha-Adrenergic Activity and Binding Affinity of alpha-Adrenoceptor Agonists and Antagonists"", J. Med. Chem., vol. 27, pp. 495-503, (1984).;;Megens, A.A.H.P., et al., ""Further Validation of in vivo and in vitro Pharmacological Procedures for Assessing the alpha2/alpha1-selectivity of Test Compounds: (2) alpha-adrenoceptor Agonists"", European Journal of Pharmacology, vol. 129, pp. 57-64, (1986).;;Timmermans, P.B.M.W.M., et al., ""alpha-Adrenoceptor Agonists and Antagonists"", Drugs of the Future, vol. 9, No. 1, pp. 41-55, (1984).;;Ruffolo, R.R., et al., ""Pharmacological & Therapeutic Applications of Alpha-2 Adrenoceptor Subtypes"", Annual Review of Pharmacology & Toxicology, vol. 32, pp. 243-279, (1993).",EXPIRED
52,SK,A3,SK 68599 A3,174-499-698-658-854,2000-06-12,2000,SK 68599 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/174-499-698-658-854,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
53,WO,A1,WO 1998/023609 A1,188-805-599-413-422,1998-06-04,1998,US 9720551 W,1997-11-21,US 3174096 P,1996-11-25,2-IMIDAZOLINYLAMINOINDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having structure (I) wherein: a) R1 is hydrogen; or alkyl; b) R2 is hydrogen; alkyl or nil; c) R3 is selected from hydrogen; unsubstituted C1-C3 alkanyl; amino, hydroxy, mercapto; C1-C3 alkylthio or alkoxy; C1-C3 alkylamino or C1-C3 dialkylamino; cyano; and halo; d) R4, R5 and R7 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstitued C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; e) when R2 is nil, bond (a) is a double bond; f) the compound is not 7-bromo-6-(2-imidazolinylamino)indazole; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters, and pharmaceutical compositions containing such novel compounds, and the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/188-805-599-413-422,Patent Application,yes,4,4,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,2,2,050-700-167-439-738;;040-445-510-060-031,1351381;;10.1128/aac.36.2.372;;pmc188444;;10.1021/jm00127a037;;2567783,"RICKETTS ET AL.: ""Further investigation of anticoccidial activity of 7-bromo-N-(2-imidazolidinylidene)-1H-indazol-6-amine"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 36, no. 2, 1992, pages 372 - 377, XP002058195;;CHAPLEO C B ET AL: ""HETEROAROMATIC ANALOGUES OF THE ALPHA2-ADRENORECEPTOR PARTIAL AGONIST CLONIDINE"", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, no. 7, July 1989 (1989-07-01), pages 1627 - 1630, XP000601554",PENDING
54,NZ,A,NZ 335882 A,034-442-288-671-294,2000-12-22,2000,NZ 33588297 A,1997-11-21,US 3174096 P;;US 9720551 W,1996-11-25,2-Imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists,"A compound of formula I wherein: R1 is hydrogen or C1-3 alkanyl, R2 is hydrogen, C1-3 alkanyl or nil, R3 is selected from hydrogen, unsubstituted C1-3 alkanyl, amino, hydroxy, mercapto, C1-3 alkylthio or alkoxy, C1-3 alkylamino, C1-3 dialkylamino, cyano and halo, R4 and R5 are each independently selected from hydrogen, unsubstituted C1-3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-3 alkylamino, C1-3 dialkylamino and halo, R7 is selected from unsubstituted C1-3 alkanyl or alkenyl, unsubstituted C1-3 alkylthio or alkoxy, hydroxy, thio and halo, and provided that when R2 is nil, bond (a) is a double bond and the compound is not 7-bromo-6-(2-imidazolinylamino)indazole, and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts and biohydrolyzable amides and esters thereof. These compounds are useful in the treatment of disorders that are modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/034-442-288-671-294,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
55,US,B1,US 6306877 B1,030-953-630-383-538,2001-10-23,2001,US 66536100 A,2000-09-19,US 66536100 A;;US 30879099 A,1999-08-09,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,"This invention involves compounds having the following structure ##STR1## as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/030-953-630-383-538,Granted Patent,yes,1,4,4,42,0,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12;;C07D235/06;;C07D215/06;;C07D417/12;;C07D215/38;;C07D277/62;;C07D215/16;;C07D215/40;;A61K31/47,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12,514/311;;546/153;;546/157;;546/159;;546/171;;514/312;;514/313,1,0,,,"CA 111: 187132, 1989.",EXPIRED
56,HU,A2,HU P0000479 A2,045-909-530-687-311,2000-09-28,2000,HU P0000479 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"A találmány (I) általánős képletű vegyületekre -, ahől a) R1hidrőgénatőm; alkilcsőpőrt vagy nincs jelen, amikőr (a) kettős kötés;b) DCR2 csőpőrt, ahől R2 hidrőgénatőm; szűbsztitűálatlan alkil-,aminő-, hidrőxi-, merkaptő-, alkil-tiő-, alkőxi-, alkil-aminő-,dialkil-aminő-csőpőrt vagy halőgénatőm; vagy ha BCR3 csőpőrt, Dnitrőgénatőm is lehet; c) B=NR9, -CR3=CR8-, -CR3=N-, CR3, tiő-, őxi-,szűlfinil- vagy szűlfőnilcsőpőrt; ahől R9 hidrőgénatőm;szűbsztitűálatlan alkil-, alkenil- vagy alkinilcsőpőrt; ciklőalkil-,ciklőalkenilcsőpőrt; és ahől R3 és R8 hidrőgénatőm; szűbsztitűálatlanalkil-, alkenil- vagy alkinilcsőpőrt; ciklőalkil-, ciklőalkenil-,szűbsztitűálatlan alkil-tiő- vagy alkőxi-hidrőxi-, merkaptő-, nitrő-,cianő-, aminő-, alkil-aminő-, dialkil-aminő-csőpőrt, vagy halőgénatőm;d) R4, R5 és R6 hidrőgénatőm; szűbsztitűálatlan alkil-, alkenil- vagyalkinilcsőpőrt; ciklőalkil-, ciklőalkenil-, szűbsztitűálatlan alkil-tiő- vagy alkőxi-, hidrőxi-, merkaptő-, nitrő-, cianő-, aminő-, alkil-aminő- vagy dialkil-aminő-csőpőrt; halőgénatőm; és -NH-NH-C (=NR10)NHRl1 csőpőrt; ahől R10 és R11 hidrőgénatőm, metil- vagy etilcsőpőrt;és ahől R4, R5 és R6 egyike és csak egyike gűanidinil-aminő-csőpőrt;és e) R7 hidrőgénatőm; szűbsztitűálatlan alkil-, alkenil- vagyalkinilcsőpőrt; ciklőalkil-, ciklőalkenil-, szűbsztitűálatlan alkil-tiő- vagy alkőxi-, hidrőxi-, merkaptő-, nitrő-, cianő-, aminő-, alkil-aminő- vagy dialkil-aminő-csőpőrt; és halőgénatőm - ésenantiőmereikre, őptikai izőmereikre, sztereőizőmereikre,diasztereőmereikre, taűtőmereikre, addíciós sóikra, biőhidrőlizálhatóamidjaikra és észtereikre, ezeket tartalmazó gyógyszerkészítményekrevőnatkőzik. ŕ",The Procter & Gamble Co.,ARES JEFFREY JOSEPH;;BOGDAN SOPHIE EVA;;CUPPS THOMAS LEE;;HENRY RAYMOND TODD;;SEIBEL WILLIAM LEE;;SHELDON RUSSEL JAMES,,https://lens.org/045-909-530-687-311,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;C07D215/38;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
57,PE,A1,PE 47099 A1,058-893-936-642-779,1999-06-12,1999,PE 00106797 A,1997-11-25,US 3174096 P,1996-11-25,COMPUESTOS DE 2-IMIDAZOLINILAMINOINDAZOL UTILES COMO AGONISTAS DE ALFA-2 ADRENORECEPTORES,"SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H o ALQUILO; R2 ES H, ALQUILO o NULO; R3 ES H, ALQUILO C1-C3, AMINO, OH, MERCAPTO,CIANO, ALQUILTIO C1-C3, ALCOXI C1-C3, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; R4, R5 Y R7 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, OH, TIO, NITRO, CN, AMINO, ALQUILAMINO C1-C3, DIALQUILAMINO C1-C3 o HALOGENO; (a) PUEDE SER UN DOBLE ENLACE CON LA CONDICION DE QUE EL COMPUESTO DE FORMULA (I) NO ES 7-BROMO-6-(2-IMIDAZOLINILAMINO)INDAZOL; SIENDO COMPUESTOS (I) PREFERIDOS: 7-ETIL-6-(2-IMIDAZOLINILAMINO)INDAZOL Y 6-(2-IMIDAZOLINILAMINO)-7-METILINDAZOL. TAMBIEN SE REFIERE A UNA COMPOSICION, QUE COMPRENDE: UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, UN ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIAS Y ADICCION, TRASTORNOS GASTROINTESTINALES, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS",PROCTER & GAMBLE,SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH;;SHELDON RUSSELL JAMES;;HENRY RAYMOND TODD;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA,,https://lens.org/058-893-936-642-779,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,C07D403/12;;A61K31/415;;A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00,,0,0,,,,DISCONTINUED
58,WO,A1,WO 1998/023596 A1,072-311-450-263-108,1998-06-04,1998,US 9720802 W,1997-11-21,US 3202396 P,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having structure (I) as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzables amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/072-311-450-263-108,Patent Application,yes,2,6,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PATENTED
59,CZ,A3,CZ 183799 A3,102-325-089-542-555,1999-09-15,1999,CZ 183799 A,1997-11-21,US 3183396 P,1996-11-25,"COMPOUND, PHARMACEUTICAL PREPARATION AND PREVENTION OR THERAPY METHOD",,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/102-325-089-542-555,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
60,NO,B1,NO 313912 B1,117-018-123-581-318,2002-12-23,2002,NO 992498 A,1999-05-25,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinylheterocykelforbindelser anvendelige som <alfa>-2 adrenoceptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/117-018-123-581-318,Granted Patent,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
61,US,A,US 5965595 A,127-092-067-061-120,1999-10-12,1999,US 75608596 A,1996-11-25,US 75608596 A;;US 47870895 A;;US 8648293 A,1993-07-01,2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists,"The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3; (b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S; (c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and (d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,MAURER PETER J;;ARES JEFFREY J;;SEIBEL WILLIAM L;;WALKER DANIEL P;;SHELDON RUSSELL JAMES;;HENRY RAYMOND T,,https://lens.org/127-092-067-061-120,Granted Patent,yes,0,36,1,3,0,A61K31/4178;;C07D405/12;;A61K31/4178;;C07D405/12,A61K31/4178;;C07D405/12,514/397,0,0,,,,EXPIRED
62,AT,T1,AT E232518 T1,157-925-708-188-255,2003-02-15,2003,AT 97949399 T,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,GUANIDINYLAMINO-HETEROCYCLISCHE VERBINDUNGEN ALS ALPHA-2 ADRENOCEPTOR AGONISTEN,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/157-925-708-188-255,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,DISCONTINUED
63,NO,B1,NO 313286 B1,072-665-076-506-015,2002-09-09,2002,NO 992503 A,1999-05-25,US 3183396 P;;US 9720550 W,1996-11-25,Guanidinylamino heterocykelforbindelser nyttige som alfa-2 adrenerge reseptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/072-665-076-506-015,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
64,EP,B1,EP 0944604 B1,074-583-062-983-703,2005-01-12,2005,EP 97948290 A,1997-11-21,US 9720802 W;;US 3202396 P,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/074-583-062-983-703,Granted Patent,yes,2,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
65,AU,A,AU 1998/074025 A,142-903-655-147-30X,1998-06-22,1998,AU 1998/074025 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,Guinidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;ARES JEFFREY JOSEPH;;SEIBEL WILLIAM LEE;;SHELDON RUSSEL JAMES;;HENRY RAYMOND TODD;;BOGDAN SOPHIE EVA,,https://lens.org/142-903-655-147-30X,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
66,CA,A1,CA 2272098 A1,074-167-534-883-688,1998-06-04,1998,CA 2272098 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having the structure (I) as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,SHELDON RUSSELL JAMES;;HENRY RAYMOND TODD;;SEIBEL WILLIAM LEE;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;ARES JEFFREY JOSEPH,,https://lens.org/074-167-534-883-688,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
67,DK,T3,DK 0944601 T3,117-605-352-364-495,2003-06-10,2003,DK 97949399 T,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,Heterocykliske quanidinylaminoforbindelser som alfa-2-adrenoceptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/117-605-352-364-495,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
68,BR,A,BR 9713536 A,150-179-305-056-980,2000-11-07,2000,BR 9713536 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,Compostos heterocìclicos de guanidinila úteis como agonistas de adrenoceptores alfa-2,"Patente de Invenção: <B>""COMPOSTOS HETEROCìCLICOS DE GUANIDILINA E COMPOSIçãO FARMACêUTICA""<D>. Esta invenção refere-se a compostos tendo estruturas (l) conforme descrito nas reivindicações; e enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sais de adição, amidas bio-hidrolisáveis e seus ésteres, bem como composições farmacêuticas contendo tais compostos. A invenção também refere-se ao uso de tais compostos para prevenir ou tratar distúrbios modulados por adrenoceptores alfa-2.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/150-179-305-056-980,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,DISCONTINUED
69,BR,A,BR 9713535 A,139-982-991-117-054,2000-03-21,2000,BR 9713535 A,1997-11-21,US 3174096 P;;US 9720551 W,1996-11-25,tagonistas alfa-2-adrenoceptor,"EPTOR""<D>. Esta invenção envolve composto possuindo a estrutura (I) onde: a) R~ 1~ é hidrogênio; ou alquila; b) R~ 2~ é hidrogênio; alquila ou nenhum; c) R~ 3~ é selecionado de hidrogênio; C~ 1~-C~ 3~; C~ 1~-C~ 3~ alquiltio ou alcóxi; C~ 1~-C~ 3~ alquilamino ou C~ 1~-C~ 3~ dialquilamino; ciano; e hacanila não-substituída, alquenila ou alquinila; cicloalcanila, cicloalquenila; C~ 1~-C~ 3~ alquiltioiano; amino; C~ 1~-C~ 3~ alquilamino ou C~ 1~-C~ 3um, ligação (a) é uma ligação dupla; f) o composto não é 7-bromo--6-(2-imidazolinilamino)indazol; e enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sais de adição, amidas icas contendo tais novos compostos e o uso de taislados por alfa-2-adrenoceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSEL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/139-982-991-117-054,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
70,SK,A3,SK 69799 A3,193-147-808-622-239,2000-06-12,2000,SK 69799 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/193-147-808-622-239,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
71,WO,A1,WO 1998/023612 A1,089-623-827-530-027,1998-06-04,1998,US 9720549 W,1997-11-21,US 3175696 P,1996-11-25,2-IMIDAZOLINYLAMINOBENZOTHIAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"The invention involves compounds having following structure (I) wherein: a) R1, R2 and R3 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, alkenyl or alkynyl; cycloalkanyl, cycloalkenyl; unsubstituted C1-C3 alkylthio or alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; b) R4 is selected from hydrogen; unsubstituted C1-C3 alkanyl; amino, hydroxy, mercapto; C1-C3 alkylthio or alkoxy; C1-C3 alkylamino or C1-C3 dialkylamino and halo; c) R5 is hydrogen; or alkyl or nil; d) where R5 is nil, bond (a) is a double bond; e) the imidazolinylamino moiety is attached to the 5- or 6- position of the benzothiazole ring; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/089-623-827-530-027,Patent Application,yes,7,12,6,42,0,C07D417/12,C07D417/12,,3,0,,,"CHEMICAL ABSTRACTS, vol. 95, no. 9, 31 August 1981, Columbus, Ohio, US; abstract no. 73170b, page 34; XP002059772;;F. L. MERCHAN ET AL., SYNTHESIS, 1982, pages 1066 - 7, XP002059771;;CHEMICAL ABSTRACTS, vol. 109, no. 21, 21 November 1988, Columbus, Ohio, US; abstract no. 190313u, page 704; XP002059773",PENDING
72,NO,D0,NO 992502 D0,134-938-695-907-49X,1999-05-25,1999,NO 992502 A,1999-05-25,US 3174096 P;;US 9720551 W,1996-11-25,2-Imidazolinylaminoindazolforbindelser nyttige som <alfa>-2 adrenerge reseptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/134-938-695-907-49X,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,DISCONTINUED
73,CO,A1,CO 4910148 A1,195-854-850-172-724,2000-04-24,2000,CO 97068606 A,1997-11-24,US 3202396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILO UTILES COMO AGONIS- TAS DE ALFA-2 ADRENOCEPTORES,"La presente invención se relaciona con compuestos que tienenla siguiente estructuraen donde:a) R1 es hidrógeno; o alquilo o nada; donde R1 es nada, el enlace (a) es un enlace doble; yb) D es CR2 donde R2 se selecciona de hidrógeno; alcanilo C1 -C3 insustituido; amino; hidroxi; mercapto; alquiltio o alcoxi C1 -C3 ; alquilamino C1 -C3 o dialquilamino C1 -C3 o halo; o cuando B es CR3 , D puede ser N;c) B es NR9 , CR3 =CR8 , CR3 =N, CR3 , S, O, SO o SO2 ; en donde R9 se selecciona de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo y en donde R3 y R8 cada uno se seleccionan independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo, alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 y halo;d) R4 , R5 y R6 cada uno se seleccionan independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo, alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 y halo; y NH-C(=NR10 )NHR11 (guanidinilo); en donde R10 y R11 se seleccionan independientemente de hidrógeno; metilo y etilo; y en donde uno o solamente uno de R4 R5 y R6 es guanidinilo;e) R7 se selecciona de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo, alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 y halo;y enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sales de adición, amidasésteres biohidrolizables, y composiciones farmacéuticas que contienen tales nuevos compuestos, y el uso de tales compuestos para prevenir o tratar trastornos modulados por alfa-2 adrenoceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/195-854-850-172-724,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/155;;A61K31/41;;A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/42;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
74,ID,A,ID 23038 A,010-462-910-809-79X,2000-01-06,2000,ID 990404 D,1997-11-21,US 3183396 P,1996-11-25,SENYAWA-SENYAWA GUANIDINILAMINO HETEROSIKLUS YANG BERGUNA SEBAGAI AGONIS ADRENOSEPTOR ALFA-2,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SHOPIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/010-462-910-809-79X,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
75,TR,T2,TR 199901467 T2,030-253-759-245-462,1999-10-21,1999,TR 9901467 T,1997-11-21,US 3183396 P,1996-11-25,Alfa-2 adrenoseptör agonistleri olarak yararli guanidinilamino heterosikl bilesikleri.,"Bu bulus Istemlerde açiklanan (I) yapisini haiz bilesiklere; bunlarin enantiomerleri, optik izomerleri, stereoizomerleri, diastereomerleri, totomerleri, ilave tuzlari, biyohidrolize edilebilir amitleri ve esterlerine ve bu yeni bilesikleri içeren farmasötik bilesimlere iliskindir. Bulus ayrica bu bilesiklerin alfa-2 adrenoseptörleri tarafindan degistirilmis bozukluklari önlemek veya tedavi etmek için kullanimina iliskindir.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/030-253-759-245-462,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
76,TR,T2,TR 199901542 T2,058-990-564-933-413,2000-01-21,2000,TR 9901542 T,1997-11-21,US 3174096 P,1996-11-25,Alfa-2 adrenoseptör agonistleri olarak yararli 2-imidazolinilaminoindazol bilesikleri.,"Bu bulus istemlerde tanimlandigi gibi (I) yapisini haiz bilesiklere; bunlarin enantiomerleri, optik izomerleri, stereoizomerleri, diastereomerleri, totomerleri, ilave tuzlari, biyohidrolize edilebilir amitleri ve esterlerine ve bu yeni bilesikleri içeren farmasötik bilesimlere iliskindir. Bulus ayrica bu bilesiklerin alfa-2 adrenoseptörleri tarafindan degistirilmis bozukluklari önlemek veya tedavi etmek için kullanimina iliskindir.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/058-990-564-933-413,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
77,US,A1,US 2001/0000345 A1,092-356-234-433-453,2001-04-19,2001,US 72790000 A,2000-12-01,US 72790000 A;;US 30878899 A;;US 3202396 P,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

   as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (2005-05-06),https://lens.org/092-356-234-433-453,Patent Application,yes,0,4,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,546/153;;549/23;;549/396,0,0,,,,EXPIRED
78,CA,C,CA 2272098 C,106-512-463-272-794,2003-11-11,2003,CA 2272098 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having the structure (1) (see figure I) wherein a) R1 is hydrogen; or C1-C3 alkanyl or C2-C3 alkenyl or nil; where R 1 is nil, bond (a) is a double bond; b) D is CR2 and R2 is selected from hydrogen; unsubstituted C1-C3 alkanyl; amino, hydroxy, mercapto; C1-C3 alkylthio or C1 - C3 alkoxy; C1-C3 alkylamino or C1-C3 dialkylamino and halo; or when B is CR3; D may be N; c) B is NR9, CR3=CR8, CR3=N, CR3, S, O, SO or SO2; wherein R9 is selected from hydrogen; and unsubstituted C1-C3 alkanyl, C2-C3 alkenyl or C2-C3 alkynyl; C3 cycloalkanyl, C3 cycloalkenyl; and wherein R3 and R8 are each independently selected from hydrogen; unsubstituted C1-C3 alkanyl, C2-C3 alkenyl or C2-C3 alkynyl; C3 cycloalkanyl, C3 cycloalkenyl; unsubstituted C1-C3 alkylthio or C1-C3 alkoxy; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino a nd halo; d) R4, R5 and R6 are each independently selected from hydrogen; unsubstitute d C1- C3 alkanyl, C2-C3 alkenyl or C2-C3 alkynyl; C3 cycloalkanyl, C3 cycloalkeny l; unsubstituted C1-C3 alkylthio or C1-C3 alkoxy; hydroxy; thio; nitro; cyano; amino; C1- C3 alkylamino or C1-C3 dialkylamino; halo; and NH-C(=NR10)NHR11 (guanidinyl ); wherein R10 and R11 are independently selected from hydrogen; methyl; and ethyl; and wherein oneand only one of R4, R5 and R6 is guanidinyl; e) R7 is selecte d from hydrogen; unsubstituted C1-C3 alkanyl, C2-C3 alkenyl or C2-C3 alkynyl; C3 cycloalkanyl, C3 cycloalkenyl; unsubstituted C1-C3 alkylthio or C1-C3 alkoxy ; hydroxy; thio; nitro; cyano; amino; C1-C3 alkylamino or C1-C3 dialkylamino and halo; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, bihydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alph a- 2 adrenoceptors.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH;;SHELDON RUSSELL JAMES;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD,,https://lens.org/106-512-463-272-794,Granted Patent,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
79,PE,A1,PE 16499 A1,187-114-376-991-170,1999-03-12,1999,PE 00106697 A,1997-11-25,US 3183396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILAMINO UTILES COMO AGONISTAS DE ALFA-2 ADRENORECEPTORES,"SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQUILO o NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; ""B"" ES NR9, CR3=CR8, S, ENTRE OTROS; ""D"" ES CR2 o SI B ES CR3, ENTONCES ""D"" PUEDE SER NITROGENO, EN DONDE: R2 ES H, ALQUILO C1-C3, ENTRE OTROS; R9 ES H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO; R3, R7 Y R8 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, ENTRE OTROS; R4, R5 Y R6 SON H, ALQUILO C1-C3, ALQUILTIO C1-C3, ALCOXI C1-C3, ENTRE OTROS, CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 ES NH-NH-C(=NR10)NHR11 (GUANIDINILAMINO), EN DONDE: R10 Y R11 SON H, METILO o ETILO; SON COMPUESTOS PREFERIDOS: [(8-METILQUINOLINA-7-IL)AMINO]GUANIDINA Y [(4-METILBENCIMIDAZOL-5-IL)AMINO]GUANIDINA. TAMBIEN SE REFIERE A LA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS SELECCIONADOS DE UN ANTIHISTAMINICO, UN ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTAS ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE LA CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIAS Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS",PROCTER & GAMBLE,SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH;;SHELDON RUSSELL JAMES;;HENRY RAYMOND TODD;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA,,https://lens.org/187-114-376-991-170,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D235/30;;C07D277/64,,0,0,,,,DISCONTINUED
80,US,A,US 5914342 A,023-235-511-563-085,1999-06-22,1999,US 15969898 A,1998-09-24,US 15969898 A;;US 75608596 A;;US 47870895 A,1995-06-07,2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists,"The subject invention relates to compounds having the structure: ##STR1## wherein (a) n is an integer from 1 to about 3; (b) X and Y are each independently selected from O, S and CH.sub.2, with at least one of X and Y being O or S; (c) R is unsubstituted, straight or branched chain alkanyl or alkanoxy having from 1 to about 3 non-hydrogen atoms; and (d) R' is selected from hydrogen, methyl, cyano, and halo; pharmaceutical compositions containing such compounds; and the use of such compounds for preventing or treating of disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,MAURER PETER J;;ARES JEFFREY J;;SEIBEL WILLIAM L;;WALKER DANIEL P;;SHELDON RUSSELL JAMES;;HENRY RAYMOND T,,https://lens.org/023-235-511-563-085,Granted Patent,yes,7,26,1,3,0,A61K31/4178;;C07D405/12;;C07D405/12;;A61K31/4178,A61K31/4178;;C07D405/12,514/397,4,3,036-707-528-796-71X;;040-445-510-060-031;;013-502-014-709-435,6311568;;10.1016/0014-2999(83)90373-4;;10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046,"Chapleo, C.B., J. C. Doxey, L. W. Frank, P.L. Myers, A.G. Roach, C.F.C. Smith & N.K. Virdee, Comparison of the Adrenoceptor Profiles of Clonidine and Two Oxygenated Arylamino Imidazolines , European Journal of Pharmacology , vol. 91 (1983), pp. 123 128.;;Chapleo, C.B., J. C. Doxey, P.L. Myers, M. Myers, C.F.C. Smith & M.R. Stillings, Effect of 1,4 Dioxanyl Substitution on the Adrenergic Activity of Some Standard Adrenoreceptor Agents , European Journal of Medical Chemistry , vol. 24 (1989), pp. 619 622.;;Chapleo, C.B., R.C.M. Butler, D.C. England, P.L. Myers, A.G. Roach, C.F.C. Smith, M.R. Stillings & I.F. Tulloch, Heteroaromatic Analogues of the 2 Adrenoreceptor Partial Agonist Clonidine , Journal of Medical Chemistry , vol. 32 (1989), pp. 1627 1630.;;Clare, K.A., M.C. Scrutton & N.T. Thompson, Effects of 2 Adrenoreceptor Agonists and of Related Compounds on Agregation of , and on Adenylate Cyclase Activity in , Human Platelets , British Journal of Pharmacology , vol. 82 (1984), pp. 467 476.",EXPIRED
81,US,B1,US 6436978 B1,029-849-643-622-627,2002-08-20,2002,US 91905301 A,2001-07-31,US 91905301 A;;US 66536100 A;;US 30879099 A;;US 3183396 P,1996-11-25,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

    as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/029-849-643-622-627,Granted Patent,yes,6,4,4,42,0,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12;;C07D235/06;;C07D215/06;;C07D417/12;;C07D215/38;;C07D277/62;;C07D215/16;;C07D215/40;;A61K31/47,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12,514/367;;514/375;;514/403;;514/415;;548/178;;548/217;;548/362.5;;548/491;;548/507,8,6,040-445-510-060-031;;013-502-014-709-435;;176-451-500-252-542;;095-061-055-274-806;;040-034-235-622-020;;010-417-946-924-13X,10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046;;6117656;;6142954;;10.1021/jm00370a011;;10.1016/0014-2999(86)90336-5;;2876906;;2876905;;10.1016/0014-2999(86)90335-3;;10.1146/annurev.pa.33.040193.001331;;10.1146/annurev.pharmtox.33.1.243;;8098595,"C.B. Chapleo, et al, ""Heteroaromatic Analogues of the alpha2-Adrenoceptor Partial Agonist Clonidine"", J. Med. Chem., vol. 32, pp. 1627-1630, (1989).;;Clare, K.A., et al., Effects of alpha2-Adrenoceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclase Activity in, Human Platelets, Br. J. Pharmac, vol. 82, pp. 467-476, (1984).;;Chapleo, C.B., ""Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of Some Standard alpha-Adrenoreceptor Agents"", Eur. J. Med. Chem., vol. 24, pp. 619-622, (1989).;;Van Meel, J.C.A., ""Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat1"", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, No. 3, pp. 760-767, (1981).;;Timmerman, P.B.M.W.M., et al., ""Quantitative Relationships Between alpha-Adrenergic Activity and Binding Affinity of alpha-Adrenoceptor Agonists and Antagonists"", J. Med. Chem., vol. 27, pp. 495-503, (1984).;;Megens, A.A.H.P., et al., ""Further Validation of in vivo and in vitro Pharmacological Procedures for Assessing the alpha2/alpha1-selectivity of Test Compounds: (2) alpha-adrenoceptor Agonists"", European Journal of Pharmacology, vol. 129, pp. 57-64, (1986).;;Timmermans, P.B.M.W.M., et al., ""alpha-Adrenoceptor Agonists and Antagonists"", Drugs of the Future, vol. 9, No. 1, pp. 41-55, (1984).;;Ruffolo, R.R., et al., ""Pharmacological & Therapeutic Applications of Alpha-2 Adrenoceptor Subtypes"", Annual Review of Pharmacology& Toxicology, vol. 32, pp. 243-279, (1993).",EXPIRED
82,NZ,A,NZ 335859 A,140-222-414-877-380,2000-11-24,2000,NZ 33585997 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,"Compounds of formula (I) may be used for preventing or treating disorders modulated by alpha-2 adrenoceptors. In formula (I); R1 is hydrogen, or alkyl or nil; provided that when R1 is nil, bond (a) is a double bond; D is CR2, where R2 is selected from hydrogen, unsubstituted C1-C3 alkanyl, amino, hydroxy, mercapto, C1-C3 alkylthio or alkoxy, C1-C3 alkylamino, C1-C3 dialkylamino and halo, or when B is CR3, D may be N; B is NR9, CR3=CR8, CR3=N, CR3, S, O, SO or SO2; wherein R9 is selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl and cycloalkenyl; and R3 and R8 are each independently selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino or C1-C3 dialkylamino and halo; R4, R5 and R6 are each independently selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino, C1-C3 dialkylamino, halo, and NH-NH-C(=NR10)NHR11 (guanidinylamino), wherein R10 and R11 are independently selected from hydrogen, methyl, and ethyl, and wherein only one of R4, R5 and R6 is guanidinylamino; and R7 is selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino or C1-C3 dialkylamino and halo.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/140-222-414-877-380,Patent Application,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,PENDING
83,CA,C,CA 2272640 C,162-244-262-917-966,2003-07-08,2003,CA 2272640 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having structure (I) as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzables amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;HENRY RAYMOND TODD;;ARES JEFFREY JOSEPH;;BOGDAN SOPHIE EVA;;CUPPS THOMAS LEE,,https://lens.org/162-244-262-917-966,Granted Patent,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
84,EP,B1,EP 0944601 B1,186-342-493-754-455,2003-02-12,2003,EP 97949399 A,1997-11-21,US 9720550 W;;US 3183396 P,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/186-342-493-754-455,Granted Patent,yes,2,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
85,US,A1,US 2002/0128481 A1,031-897-083-420-290,2002-09-12,2002,US 7128402 A,2002-02-08,US 7128402 A;;US 72790000 A;;US 30878899 A;;US 3202396 P,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

   as described in the claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/031-897-083-420-290,Patent Application,yes,0,3,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,544/353;;546/153;;546/159;;544/283;;548/152;;548/217;;548/304.4;;548/483;;548/484,0,0,,,,DISCONTINUED
86,CO,A1,CO 4910166 A1,042-240-973-179-569,2000-04-24,2000,CO 97068615 A,1997-11-24,US 3174096 P,1996-11-25,COMPUESTOS 2-IMIDAZOLINILAMINOINDAZOL UTILES COMO AGONISTAS DE 2-ALFA ADRENOCEPTORES,"La presente invención se relaciona con compuestos que tienenla siguiente estructura en donde: a) R1 es hidrógeno; o alquilo; b) R2 es hidrógeno; o alquilo o nada; c) R3 se selecciona de hidrógeno; alcanilo C1 -C3 insustituido; amino; hidroxi; mercapto; alquiltio o alcoxi; alquilamino C1 -C3 ; o dialquilamino C1 -C3 ; ciano y halo; d) R4 , R5 y R7 se seleccionan cada uno independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; amino; hidroxi; mercapto; alquiltio o alcoxi C1 -C3 ; tio; nitro; ciano; amino; alquilamino C1 -C3 ; dialquilamino C1 -C3 ;e) cuando R2 es nada, el enlace (a) es un enlace doble; f) el compuesto no es 7-bromo-6-(2- imidazolinilamino)-indazol; y enantiómeros, isómeros ópticos, estereoisómeros, diastereómeros, tautómeros, sales de adición, amidas y ésteres biohidrolizables, y composiciones farmacéuticas que contienen tales nuevos compuestos, y el uso de tales compuestos para prevenir o tratar trastornos modulados por alfa-2 adrenoceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/042-240-973-179-569,Patent Application,no,0,0,22,22,0,C07D403/12;;A61P1/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;A61P9/00;;C07D403/12;;A61K31/475,A61K31/155;;A61K31/415;;A61K31/4178;;A61P1/00;;A61P9/00;;A61P11/00;;A61P25/00;;A61P27/02;;A61P27/16;;A61P43/00;;C07D403/12,,0,0,,,,PENDING
87,AU,B2,AU 729421 B2,049-918-963-072-574,2001-02-01,2001,AU 1998/074025 A,1997-11-21,US 3183396 P;;US 9720550 W,1996-11-25,Guinidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/049-918-963-072-574,Granted Patent,no,2,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,C07D215/38;;A61K31/404;;A61K31/416;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
88,US,B2,US 6391878 B2,042-610-482-606-592,2002-05-21,2002,US 72790000 A,2000-12-01,US 72790000 A;;US 30878899 A;;US 3202396 P,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

    as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,THE BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA (2005-05-06),https://lens.org/042-610-482-606-592,Granted Patent,yes,9,29,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,514/249;;514/312;;514/313;;514/314;;544/353;;544/354;;544/355;;544/356;;546/156,16,6,040-445-510-060-031;;013-502-014-709-435;;176-451-500-252-542;;095-061-055-274-806;;040-034-235-622-020;;010-417-946-924-13X,10.1021/jm00127a037;;2567783;;10.1111/j.1476-5381.1984.tb10782.x;;6145472;;pmc1987046;;6117656;;6142954;;10.1021/jm00370a011;;10.1016/0014-2999(86)90336-5;;2876906;;2876905;;10.1016/0014-2999(86)90335-3;;10.1146/annurev.pa.33.040193.001331;;10.1146/annurev.pharmtox.33.1.243;;8098595,"CA 83:188388, hughes, 1975.*;;CA 107:77202, Taylor, 1986.*;;CA 125:264954, Acheampong, 1996.*;;CA 123:217719, 1995.*;;C.B. Chapleo, et al, ""Heteroaromatic Analogues of the alpha2-Adrenoceptor Partial Agonist Clonidine"", J. Med. Chem., vol. 32, pp. 1627-1630, (1989).;;Timmermans, P.B.M.W.M, et al, ""12.1 alpha-Adrenergic Receptors"", Neurotransmitter and Autocoid Receptors, pp. 133-185.;;Clare, K.A., et al., Effects of alpha2-Adrenoceptor Agonists and of Related Compounds on Aggregation of, and on Adenylate Cyclase Activity in, Human Platelets, Br. J. Pharmac, vol. 82, pp. 467-476, (1984).;;Chapleo, C.B., ""Effect of 1,4-Dioxanyl Substitution on the Adrenergic Activity of Some Standard alpha-Adrenoreceptor Agents"", Eur. J. Med. Chem., vol. 24, pp. 619-622, (1989).;;Van Meel, J.C.A., ""Selectivity of Some Alpha Adrenoceptor Agonists for Peripheral Alpha-1 and Alpha-2 Adrenoceptors in the Normotensive Rat1"", The Journal of Pharmacology and Experimental Therapeutics, vol. 219, No. 3, pp. 760-767, (1981).;;Timmerman, P.B.M.W.M., et al., ""Quantitative Relationships Between alpha-Adrenergic Activity and Binding Affinity of alpha-Adrenoceptor Agonists and Antagonists"", J. Med. Chem., vol. 27, pp. 495-503, (1984).;;Megens, A.A.H.P., et al., ""Further Validation of in vivo and in vitro Pharmacological Procedures for Assessing the alpha2/alpha1-selectivity of Test Compounds: (2) alpha-adrenoceptor Agonists"", European Journal of Pharmacology, vol. 129, pp. 57-64, (1986).;;Timmermans, P.B.M.W.M., et al., ""alpha-Adrenoceptor Agonists and Antagonists"", Drugs of the Future, vol. 9, No. 1, pp. 41-55, (1984).;;Ruffolo, R.R., et al., ""Pharmacological & Therapeutic Applications of Alpha-2 Adrenoceptor Subtypes"", Annual Review of Pharmacology & Toxicology, vol. 32, pp. 243-279, (1993).;;Chemical Abstracts, 102: 168273, 1984.;;Chemical Abstracts, 132: 260666, Dykens, 2000.;;Chemical Abstracts, 132:233047, Hasegawa, 2000.",EXPIRED
89,ID,A,ID 23857 A,040-964-432-613-159,2000-05-25,2000,ID 990410 A,1997-11-21,US 3202396 P,1996-11-25,SENYAWA-SENYAWA GUANIDINIL HETEROSIKLIK YANG BERGUNA SEBAGAI AGONIS ADRENOCEPTOR ALFA-2,,PROCTER & GAMBLE,CUPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/040-964-432-613-159,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
90,HU,A2,HU P0000312 A2,080-931-011-011-416,2000-09-28,2000,HU P0000312 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM,"(57) A találmány (I) általánős képletű vegyületekre - amelyekképletében a) Rl hidrőgénatőm, alkilcsőpőrt vagy nincs jelen; ahől R1nincs jelen, (a) kettős kötés; b) DCR2 csőpőrt, ahől R2 hidrőgénatőm,alkil-, aminő-, hidrőxi-, merkaptő-, alkil-tiő-, alkőxi-, alkil-aminő-, dialkil-aminő-csőpőrt, halőgénatőm; vagy ha BCR3 csőpőrt, Dnitrőgénatőm is lehet; c) B =NR9, -CR3=CR8-, -CR3=N-, CR3 csőpőrt,tiő-, őxi-, szűlfinil- vagy szűlfőnilcsőpőrt; R9 hidrőgénatőm, alkil-,alkenil-, alkinil-, ciklőalkil-, ciklőalkenilcsőpőrt; R3 és R8hidrőgénatőm, alkil-, alkenil-, alkinil-, ciklőalkil-, ciklőalkenil-,alkil-tiő-, alkőxi-, hidrőxi-, merkaptő-, nitrő-, cianő-, aminő-,alkil-aminő-, dialkil-aminő-csőpőrt, halőgénatőm; d) R4, R5 és R6hidrőgénatőm, alkil-, alkenil-, alkinil-, ciklőalkil-, ciklőalkenil-,alkil-tiő-, alkőxi-, hidrőxi-, merkaptő-, nitrő-, cianő-, aminő-,alkil-aminő-, dialkil-aminő-csőpőrt, halőgénatőm, vagy -NH-C(=NR10)NHRl1 csőpőrt; R10 és R11 hidrőgénatőm, metil- vagyetilcsőpőrt; ahől R4, R5, és R6 egyike gűanidinilcsőpőrt; és e) R7hidrőgénatőm, alkil-, alkenil-, alkinil-, ciklőalkil-, ciklőalkenil-,alkil-tiő-, alkőxi-, hidrőxi-, merkaptő-, nitrő-, cianő-, aminő-,alkil-aminő-, dialkil-aminő-csőpőrt, halőgénatőm - és a vegyületekenantiőmereire, őptikai izőmereire, sztereőizőmereire,diasztereőmereire, taűtőmereire, addíciós sóira, biőhidrőlizálhatóamidjaira és észtereire, az új vegyületeket tartalmazógyógyszerkészítményekre, valamint a vegyületek a2-adrenőreceptőrőkáltal mődűlált rendellenességek megelőzésére vagy kezelésre történőfelhasználására vőnatkőzik. ŕ",The Procter and Gamble Co.,ARES JEFFREY JOSEPH;;BOGDAN SOPHIE EVA;;CUPPS THOMAS LEE;;HENRY RAYMOND TODD;;SEIBEL WILLIAM LEE;;SHELDON RUSSEL JAMES,,https://lens.org/080-931-011-011-416,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
91,CO,A1,CO 4910167 A1,130-416-743-441-96X,2000-04-24,2000,CO 97068613 A,1997-11-24,US 6183396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILAMINO UTILES COMO AGONISTAS DE ALFA-2 ADRENOCEPTORES,"La presente invención se relaciona con compuestos que tienenla siguiente estructura: a) R1 es hidrógeno; o alquilo o nada; donde R1 es nada, el enlace (a) es un enlace doble; b) D es CR2 donde R2 se selecciona de hidrógeno; alcanilo C1 -C3 insustituido; amino, hidroxi, mercapto; alquiltio o alcoxi C1 -C3 ; alquilamino C1 -C3 ; o dialquilamino C1 -C3 y halo; o cuando B es CR3 , D puede ser N;c) B es NR9 , CR3 =CR8 , CR3 =N, CR3 , S, O SO o SO2 ; en donde R9 se selecciona de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo y en donde R3 y R8 cada uno se seleccionan independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 y halo; d) R4 , R5 y R6 cada uno se selecciona independientemente de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 (insustituido; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1 -C3 ; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 ; halo; y NH-NH-C(=NR10 ) NHR11 (guanidinilamino); en donde R10 y R11 se seleccionan independientemente de hidrógeno; metilo; y etilo; y en donde uno y solamente uno de R4 , R5 y R6 es guanidinilamino; e) R7 se selecciona de hidrógeno; alcanilo, alquenilo o alquinilo C1 -C3 insustituido; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1 -C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1 -C3 o dialquilamino C1 -C3 y halo; y enantiómeros, isómero ópticos, estereoisómeros, diastereómeros, tautómeros, sales de adición, amidas y ésteres biohidrolizables, y las composiciones farmacéuticas que contienen tales compuestos y el uso de tales compuestos para prevenir o tratar transtornos modulados por alfa-2 adrenoceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/130-416-743-441-96X,Patent Application,no,0,0,1,1,0,,A61K31/155;;A61K31/41;;A61K31/42,,0,0,,,,PENDING
92,US,A1,US 2002/0028950 A1,144-758-717-328-830,2002-03-07,2002,US 91905301 A,2001-07-31,US 91905301 A;;US 66536100 A;;US 30879099 A;;US 3183396 P,1996-11-25,Guanidinylamino heterocycle compunds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

   as described in the claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/144-758-717-328-830,Patent Application,yes,0,4,4,42,0,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12;;C07D235/06;;C07D215/06;;C07D417/12;;C07D215/38;;C07D277/62;;C07D215/16;;C07D215/40;;A61K31/47,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12,548/306.4;;548/307.4,0,0,,,,EXPIRED
93,PE,A1,PE 16399 A1,164-671-269-133-864,1999-03-12,1999,PE 00107097 A,1997-11-25,US 3202396 P,1996-11-25,COMPUESTOS HETEROCICLICOS DE GUANIDINILO UTILES COMO AGONISTAS DE ALFA-2 ADRENORECEPTORES,"SE REFIEREN A COMPUESTOS DE FORMULA (I), EN DONDE: R1 ES H, ALQUILO o NO EXISTE, CUANDO EL ENLACE (a) ES UN DOBLE ENLACE; ""B"" ES NR9, CR3=CR8, S, ENTRE OTROS; ""D"" ES CR2 o SI B ES CR3, ENTONCES ""D"" PUEDE SER NITROGENO, EN DONDE: R2 ES H, ALQUILO C1-C3, AMINO, ENTRE OTROS; R9 ES H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO; R3, R7 Y R8 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ALQUINILO C1-C3, CICLOALQUILO, CICLOALQUENILO, ALQUILTIO C1-C3, ALCOXI C1-C3, ENTRE OTROS; R4, R5 Y R6 SON H, ALQUILO C1-C3, ALQUENILO C1-C3, ENTRE OTROS, CON LA CONDICION DE QUE UNO DE R4, R5 Y R6 ES NH-C(=NR10)NHR11 (GUANIDINILO), EN DONDE: R10 Y R11 ES H, METILO Y ETILO; SIENDO UN COMPUESTO (I) PREFERIDO: (4-METILBENCIMIDAZOL-5-IL)GUANIDINA. TAMBIEN SE REFIERE A LA COMPOSICION QUE COMPRENDE UN COMPUESTO DE FORMULA (I) Y UNO O MAS PRINCIPIOS ACTIVOS COMO UN ANTIHISTAMINICO, ANTIINFLAMATORIO, ENTRE OTROS. LOS COMPUESTOS DE FORMULA (I) ACTUAN COMO AGONISTA DE ALFA 2 ADRENORECEPTORES, SIENDO UTILES EN EL TRATAMIENTO DE CONGESTION NASAL, OTITIS MEDIA, SINUSITIS, ASMA, DOLOR, MIGRANA, ABUSO DE SUSTANCIA Y ADICCION, TRASTORNO GASTROINTESTINAL, ULCERA, HIPERACIDEZ ESTOMACAL, HIPERTROFIA PROSTATICA BENIGNA, ENTRE OTROS",PROCTER & GAMBLE,SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH;;SHELDON RUSSELL JAMES;;HENRY RAYMOND TODD;;CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA,,https://lens.org/164-671-269-133-864,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,C07D235/30;;A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/425;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64;;C07D277/82,,0,0,,,,EXPIRED
94,CA,A1,CA 2272640 A1,195-245-223-948-120,1998-06-04,1998,CA 2272640 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,GUANIDINYL HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,"This invention involves compounds having structure (I) as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzables amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors.",PROCTER & GAMBLE,SEIBEL WILLIAM LEE;;BOGDAN SOPHIE EVA;;CUPPS THOMAS LEE;;SHELDON RUSSELL JAMES;;ARES JEFFREY JOSEPH;;HENRY RAYMOND TODD,,https://lens.org/195-245-223-948-120,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
95,NO,L,NO 992503 L,002-481-676-289-135,1999-07-23,1999,NO 992503 A,1999-05-25,US 3183396 P;;US 9720550 W,1996-11-25,Guanidinylamino heterocykelforbindelser nyttige som <alfa>-2 adrenerge reseptoragonister,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/002-481-676-289-135,Abstract,no,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;C07D215/38;;A61K31/4184;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
96,NZ,A,NZ 336010 A,025-451-056-402-704,2001-05-25,2001,NZ 33601097 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,"A compound of the following formula wherein; R1 is hydrogen; or alkyl or nil; where R1 is nil, bond (a) is a double bond; D is CR2 and R2 is selected from hydrogen; unsubstituted C1-C3 alkanyl, amino, hydroxy, mercapto, C1-C3 alkylthio or alkoxy, C1-C3 alkylamino or C1-C3 dialkylamino and halo, or when B is CR3, D may be N B is NR9, CR3=CR8, CR3=N, CR3, S, O, SO or SO2; wherein R9 is selected from hydrogen, and unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl and wherein R3 and R8 are each independently selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino or C1-C3 dialkylamino and halo R4, R5 and R6 are each independently selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino or C1-C3 dialkylamino, halo, and NH-C(=NR10)NHR11 (guanidinyl); wherein R10 and R11 are independently selected from hydrogen, methyl and ethyl; and wherein one and only one of R4, R5 and R6 is guanidinyl; R7 is selected from hydrogen, unsubstituted C1-C3 alkanyl, alkenyl or alkynyl, cycloalkanyl, cycloalkenyl, unsubstituted C1-C3 alkylthio or alkoxy, hydroxy, thio, nitro, cyano, amino, C1-C3 alkylamino or C1-C3 dialkylamino and halo; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof. Also disclosed is the use of compounds of the above formula for preventing or treating disorders modulated by alpha-2 adrenoceptors",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/025-451-056-402-704,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
97,AU,B2,AU 730369 B2,036-729-418-410-000,2001-03-08,2001,AU 1998/054381 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/036-729-418-410-000,Granted Patent,no,2,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
98,EP,A1,EP 0944601 A1,034-374-844-336-912,1999-09-29,1999,EP 97949399 A,1997-11-21,US 9720550 W;;US 3183396 P,1996-11-25,GUANIDINYLAMINO HETEROCYCLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS,,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/034-374-844-336-912,Patent Application,yes,0,0,31,42,0,C07D215/40;;C07D235/06;;A61K9/0019;;A61K9/0043;;A61K9/0048;;A61K9/0056;;A61K9/008;;A61K9/0095;;A61K9/06;;A61K47/38;;A61K9/2009;;A61K9/2018;;A61K9/2054;;A61K9/2059;;A61P1/00;;A61P1/04;;A61P11/00;;A61P25/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;A61P9/00;;C07D215/40,A61K31/404;;A61K31/416;;A61K31/4184;;C07D215/38;;A61K31/427;;A61K31/47;;A61P1/00;;A61P1/04;;A61P9/00;;A61P11/00;;A61P25/30;;A61P27/02;;A61P27/16;;A61P29/00;;A61P43/00;;C07D209/08;;C07D209/30;;C07D215/40;;C07D231/56;;C07D235/06;;C07D235/08;;C07D277/64,,0,0,,,,EXPIRED
99,US,A1,US 2002/0095039 A1,042-855-927-914-308,2002-07-18,2002,US 2078001 A,2001-12-14,US 2078001 A;;US 91905301 A;;US 66536100 A;;US 30879099 A;;US 3183396 P;;US 3175696 P,1996-11-25,Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists,"
    This invention involves compounds having the following structure: 

   as described in the Claims; and enantiomers, optical isomers, stereoisomers, diastereomers, tautomers, addition salts, biohydrolyzable amides and esters thereof, as well as pharmaceutical compositions comprising such novel compounds. The invention also relates to the use of such compounds for preventing or treating disorders modulated by alpha-2 adrenoceptors. 
",CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/042-855-927-914-308,Patent Application,yes,0,5,4,42,0,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12;;C07D235/06;;C07D215/06;;C07D417/12;;C07D215/38;;C07D277/62;;C07D215/16;;C07D215/40;;A61K31/47,A61K31/47;;C07D215/06;;C07D215/16;;C07D215/38;;C07D215/40;;C07D235/06;;C07D277/62;;C07D417/12,546/156;;546/159;;548/152;;548/162;;548/167;;548/217;;548/306.4;;548/307.4;;544/353,0,0,,,,DISCONTINUED
100,CZ,A3,CZ 184099 A3,149-707-496-315-13X,1999-11-17,1999,CZ 184099 A,1997-11-21,US 3202396 P,1996-11-25,"COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND PREVENTION OR TREATMENT METHOD",,PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/149-707-496-315-13X,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,PENDING
101,AU,A,AU 1998/054381 A,148-066-931-862-24X,1998-06-22,1998,AU 1998/054381 A,1997-11-21,US 3202396 P;;US 9720802 W,1996-11-25,Guanidinyl heterocycle compounds useful as alpha-2 adrenoceptor agonists,,BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA THE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/148-066-931-862-24X,Patent Application,no,0,0,36,36,0,C07D215/38;;C07D235/06;;C07D277/62;;A61P1/00;;A61P1/04;;A61P1/12;;A61P11/02;;A61P13/08;;A61P25/00;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;A61P9/00;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;C07D235/06;;C07D235/06;;C07D277/62;;C07D215/38,A61K31/415;;A61K31/416;;A61K31/4184;;A61K31/421;;A61K31/428;;A61K31/47;;A61P1/00;;A61P1/04;;A61P1/12;;A61P9/04;;A61P9/06;;A61P9/10;;A61P9/12;;A61P11/02;;A61P13/08;;A61P25/02;;A61P25/06;;A61P25/32;;A61P25/36;;A61P27/02;;A61P27/06;;A61P27/16;;C07D215/18;;C07D215/38;;C07D231/56;;C07D235/06;;C07D235/08;;C07D263/56;;C07D277/62;;C07D277/64,,0,0,,,,EXPIRED
102,CO,A1,CO 4910168 A1,180-965-340-585-243,2000-04-24,2000,CO 97068605 A,1997-11-24,US 3175696 P,1996-11-25,COMPUESTOS DE 2-IMIDAZOLINILAMINOBENZOTIAZOL UTILES COMO AGONISTAS DE ALFA-2 ADRENOCEPTORES,"La presente invención se relaciona con compuestos que tienenla siguiente estructura:en donde: a) R1, R2 y R3 se seleccionan cada uno independientemente de hidrógeno, alcanilo, alquenilo o alquinilo C1-C3 insustituido; cicloalcanilo, cicloalquenilo; alquiltio o alcoxi C1-C3 insustituido; hidroxi; tio; nitro; ciano; amino; alquilamino C1-C3 o dialquilamino C1-C3 y halo; b) R4 se selecciona de hidrógeno; alcanilo C1-C3 insustituido; amino, hidroxi, mercapto; alquiltio o alcoxi C1-C3; alquilamino C1-C3 o dialquilamino C1-C3 y halo; c) R5 es hidrógeno, o alquilo o nada; d) donde R5 es nada, el enlace (a) es un enlace doble; y e) la mitad de imidazolinilamino está unida a la 5- o 6-posición del anillo de benzotiazol; y enantiómeros, isómeros ópticos, esteroisómeros, diastereómeros, tautómeros, sales de adición amidas y ésteres biohibrolizables, y composiciones farmacéuticas que contienen tales nuevos compuestos, y el uso de tales compuestos para prevenir o tratar trastornos modulados por alfa-2 adrenoceptores.",PROCTER & GAMBLE,CUPPS THOMAS LEE;;BOGDAN SOPHIE EVA;;HENRY RAYMOND TODD;;SHELDON RUSSELL JAMES;;SEIBEL WILLIAM LEE;;ARES JEFFREY JOSEPH,,https://lens.org/180-965-340-585-243,Patent Application,no,0,0,6,42,0,C07D417/12,A61K31/415;;A61K31/425;;C07D417/12,,0,0,,,,PENDING
